Subscribe to RSS

DOI: 10.1055/s-0045-1802634
Insights into Duodenal Adenocarcinoma: Clinical Presentation, Survival Outcomes, and Treatment Trends—A Long-Term Follow-Up Study
Funding None.

Abstract
Introduction Duodenal adenocarcinoma (DA) is a rare and aggressive malignancy, representing less than 0.5% of all gastrointestinal cancers. It constitutes a significant portion (55.7%) of small bowel adenocarcinomas, most of which arise in the second part of the duodenum, followed by the third and fourth parts. Despite its rarity, DA presents substantial challenges in diagnosis and treatment due to its aggressive nature and often insidious onset.
Objectives The aim of the study is to investigate the clinical presentation, prognostic factors, survival outcomes, and treatment strategies in DA, with a focus on surgical and adjuvant therapeutic interventions. Additionally, the study aims to elucidate patterns of recurrence and identify areas for future research to optimize therapeutic approaches and enhance patient care.
Materials and Methods This retrospective observational study (2015–2023) analyzed patients aged 18 to 90 years with DA. Data from case sheets, laboratory investigations, and medication charts were reviewed. This study aims to explain demographic characteristics, clinical presentations, treatment trends, and survival outcomes to improve therapeutic strategies and patient care in DA patients, excluding other gastrointestinal cancers
Results The study examined 10 cases of DA diagnosed between 2015 and 2023. The patient cohort had an equal gender distribution, with ages ranging from 53 to 83 years. Chief presenting symptoms included abdominal pain (90%) and vomiting (50%). Tumor markers were elevated in 40% of patients. Tumor locations predominantly included the D2 region. Three patients underwent Whipple's surgery and three received chemotherapy with curative intent.
Conclusion The study highlights the challenges associated with DA, including its rare incidence, clinical presentations, and variable treatment outcomes. Surgical interventions such as the Whipple procedure and adjuvant chemotherapy show promise in improving survival rates. Further studies with larger cohorts are essential to better understand the disease, refine therapeutic strategies formulate separate guidelines for DA, and enhance patient outcomes.
Clinical trial registry number: N/A.
Consent
A wavier of consent was granted by the Father Muller Institutional Ethics Committee (FMIEC) of Father Muller Research Centre (IRB approval number: FMIEC/CCM/348/2024; date of approval: May 15, 2024).
Authors' Contributions
J.F.J. contributed to concepts, design, definition of intellectual content, literature search, clinical studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing, manuscript review. S.R.C. contributed to concepts, design, literature search, clinical studies, data analysis, manuscript preparation, manuscript editing, manuscript review. N.S. contributed to concepts, design, definition of intellectual content, literature search, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing, manuscript review. D.S. contributed to concepts, design, manuscript preparation, manuscript review.
Publication History
Article published online:
12 February 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Poultsides GA, Huang LC, Cameron JL. et al. Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment. Ann Surg Oncol 2012; 19 (06) 1928-1935
- 2 Kim MJ, Choi SB, Han HJ. et al. Clinicopathological analysis and survival outcome of duodenal adenocarcinoma. Kaohsiung J Med Sci 2014; 30 (05) 254-259
- 3 Zenali M, Overman MJ, Rashid A. et al. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol 2013; 44 (12) 2792-2798
- 4 Bal A, Joshi K, Vaiphei K, Wig JD. Primary duodenal neoplasms: a retrospective clinico-pathological analysis. World J Gastroenterol 2007; 13 (07) 1108-1111
- 5 Meijer LL, Alberga AJ, de Bakker JK. et al. Outcomes and treatment options for duodenal adenocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol 2018; 25 (09) 2681-2692
- 6 Kelsey CR, Nelson JW, Willett CG. et al. Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 69 (05) 1436-1441
- 7 Shapiro J, van Lanschot JJB, Hulshof MCCM. et al; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16 (09) 1090-1098
- 8 Jiang S, Zhao R, Li Y. et al. Prognosis and nomogram for predicting postoperative survival of duodenal adenocarcinoma: a retrospective study in China and the SEER database. Sci Rep 2018; 8 (01) 7940
- 9 Onkendi EO, Boostrom SY, Sarr MG. et al. 15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas. J Gastrointest Surg 2012; 16 (04) 682-691
- 10 National Comprehensive Cancer Network (NCCN) Web site. Accessed May 1, 2024 at: https://www.nccn.org/
- 11 Solej M, D'Amico S, Brondino G, Ferronato M, Nano M. Primary duodenal adenocarcinoma. Tumori 2008; 94 (06) 779-786
- 12 Sarma DP, Weilbaecher TG. Adenocarcinoma of the duodenum. J Surg Oncol 1987; 34 (04) 262-263
- 13 Moss WM, McCart PM, Juler G, Miller DR. Primary adenocarcinoma of the duodenum. Arch Surg 1974; 108 (06) 805-807
- 14 Cloyd JM, George E, Visser BC. Duodenal adenocarcinoma: advances in diagnosis and surgical management. World J Gastrointest Surg 2016; 8 (03) 212-221
- 15 Burasakarn P, Higuchi R, Nunobe S. et al; Japan Duodenal Cancer Guideline Committee. Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis. Int J Clin Oncol 2021; 26 (03) 450-460
- 16 Ecker BL, McMillan MT, Datta J. et al. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: a propensity score-matched analysis of a nationwide clinical oncology database. Cancer 2017; 123 (06) 967-976
- 17 Bartel MJ, Puri R, Brahmbhatt B. et al. Endoscopic and surgical management of nonampullary duodenal neoplasms. Surg Endosc 2018; 32 (06) 2859-2869
- 18 Tesarikova J, Skalicky P, Kurfurstova D. et al. Surgical treatment of duodenal adenocarcinoma: ampullary vs. non-ampullary, short- and long-term outcomes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2022; 166 (03) 290-296
- 19 Kummar S, Ciesielski TE, Fogarasi MC. Management of small bowel adenocarcinoma. Oncology (Williston Park) 2002; 16 (10) 1364-1369 , discussion 1370, 1372–1373
- 20 Liu J, Cui C, Yuan L. et al. Advanced duodenal carcinoma: chemotherapy efficacy and analysis of prognostic factors. Oncol Transl Med 2016; 2 (01) 16-20